Institution
Vanderbilt University
Education•Nashville, Tennessee, United States•
About: Vanderbilt University is a education organization based out in Nashville, Tennessee, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 45066 authors who have published 106528 publications receiving 5435039 citations. The organization is also known as: Vandy.
Topics: Population, Cancer, Poison control, Breast cancer, Receptor
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, a suite of programs for multiconfiguration or configuration-interaction relativistic atomic structure calculations with large configuration state function lists is described, where atomic orbitals are taken to be four-component spinors.
800 citations
[...]
TL;DR: The rapid local capture of TGFα by the EGFR has fundamental biological importance and is a phenomenon that is critical in diverse biological processes such as vulva development in the nematode Caenorhabditis elegans (C. elegans) and hair follicle organization in mammals.
797 citations
TL;DR: Evaluated studies indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, oesophageal, breast, lung, and bladder cancers.
Abstract: Chemoprevention has been considered as a possible approach for cancer prevention. A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past decade. Recent epidemiological studies and clinical trials indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, oesophageal, breast, lung, and bladder cancers. The best known targets of NSAIDs are cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandins (PGs) and thromboxane. COX-2 derived prostaglandin E(2)(PGE(2)) can promote tumour growth by binding its receptors and activating signalling pathways which control cell proliferation, migration, apoptosis, and/or angiogenesis. However, the prolonged use of high dosages of COX-2 selective inhibitors (COXIBs) is associated with unacceptable cardiovascular side effects. Thus it is crucial to develop more effective chemopreventive agents with minimal toxicity. Recent efforts to identify the molecular mechanisms by which PGE(2) promotes tumour growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment.
796 citations
796 citations
TL;DR: Current paradigms of targeting ERBB receptors with cancer therapeutics and the understanding of mechanisms of action and resistance to these drugs are discussed.
794 citations
Authors
Showing all 45403 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Walter C. Willett | 334 | 2399 | 413322 |
| Meir J. Stampfer | 277 | 1414 | 283776 |
| John Q. Trojanowski | 226 | 1467 | 213948 |
| Robert M. Califf | 196 | 1561 | 167961 |
| Matthew Meyerson | 194 | 553 | 243726 |
| Scott M. Grundy | 187 | 841 | 231821 |
| Tony Hunter | 175 | 593 | 124726 |
| David R. Jacobs | 165 | 1262 | 113892 |
| Donald E. Ingber | 164 | 610 | 100682 |
| L. Joseph Melton | 161 | 531 | 97861 |
| Ralph A. DeFronzo | 160 | 759 | 132993 |
| David W. Bates | 159 | 1239 | 116698 |
| Charles N. Serhan | 158 | 728 | 84810 |
| David Cella | 156 | 1258 | 106402 |
| Jay Hauser | 155 | 2145 | 132683 |